ERNA News & Events

Ernexa Therapeutics files $50M mixed securities shelf

Ernexa Therapeutics announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share and accompanying warrant. The warrants will have an exercise price of $0.68 per share, will be exercisable upon issuance, and will expire on the earlier to occur of the five-year anniversary of the initial issuance date, or the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. The closing of the offering is expected to occur on or about February 10, subject to the satisfaction of customary closing conditions. Brookline Capital Markets, a division of Arcadia Securities is acting as the exclusive placement agent for the offering.

Ernexa Therapeutics announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program, JEAP, an initiative launched by the Japan External Trade Organization, JETRO. As a selected participant, Ernexa will receive expert-led mentoring and market-entry guidance focused on Japan's regulatory, clinical and commercial landscape. The program also provides direct engagement opportunities with leading Japanese research and development organizations, including CDMOs and CROs, to explore potential collaborations across development, manufacturing and clinical execution.